Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Espoo – page 28

385 clinical trials in Espoo, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Espoo at a glance
385
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

385 trials in Espoo

Open in trial search

Sickle cell anaemia+1

Not recruiting

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crizanlizumab
  • Sponsor:Novartis Pharma AG

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Chronic myeloid leukaemia

Not recruiting

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Fibrodysplasia ossificans progressiva

Not recruiting

Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Garetosmab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Espoo

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on vaccine development for multiple respiratory viruses, including studies of new formulations against influenza, RSV, and pneumococcal infections. Clinical trials are evaluating innovative immunization approaches for various age groups.

  • Influenza Vaccines
  • RSV Prevention
  • Pneumococcal Protection

Particular emphasis on protecting vulnerable populations such as infants, toddlers, and adults over 60 years old.

02 Cardiovascular Health

Advanced research in cardiovascular medicine, focusing on preventing stroke in atrial fibrillation patients and developing new treatments for acute myocardial infarction. Studies include innovative drug therapies and preventive measures.

  • Stroke Prevention
  • Heart Attack Management
  • Blood Clot Prevention

Trials are investigating new anticoagulants and emergency interventions for heart conditions.

03 Surgical and Specialized Care

Innovative research in surgical procedures and specialized medical conditions, including studies on frostbite treatment, plastic surgery outcomes, and post-operative care protocols.

  • Surgical Complications
  • Emergency Medicine
  • Post-Operative Care

Focus on improving surgical outcomes and developing better treatment protocols for specialized conditions.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.